Home Blog

Loblaw Q1 2025: Strong Retail Growth, Pharmacy Expansion & ESG Gains

0
The company has demonstrated in the first quarter of 2025, it’s that stability isn’t boring — it’s deliberate. In a landscape where volatility often steals the headlines, Canada’s largest retailer has posted a solid set of results, marked by steady revenue growth, disciplined cost management, and a firm grip on operational priorities.

With revenue climbing 4.1% to $14.1 billion and adjusted diluted earnings per share up 9.3%, the company hasn’t just maintained its footing — it has nudged itself forward with quiet authority. But what’s most revealing about these results isn’t what they say at a glance; it’s how they reflect a company deep in tune with the shifting rhythms of Canadian retail.

At the heart of this performance is a clear understanding of what consumers are after in 2025. Not flash, not novelty — just reliability. Food inflation may be cooling, but household budgets are still tight. Loblaw has responded not with sweeping transformations but with a series of smart, calibrated moves: tailored promotions, loyalty-driven incentives, and measured investment in physical and digital infrastructure.

The PC Optimum™ programme continues to be a jewel in the crown. It’s no longer just a rewards system; it’s a behavioural insight engine, nudging spending habits and anchoring customer loyalty. That loyalty, in turn, translated into a 2.2% rise in same-store sales for food retail — not a spike, but a steady pulse that reflects both consistency and trust. More importantly, while store traffic held steady, shoppers spent more per visit — a telling detail that underpins much of Loblaw’s sales momentum.

In its drug retail division, anchored by Shoppers Drug Mart, same-store sales rose 3.8%, with pharmacy and healthcare services seeing 6.4% growth. These are encouraging signs in a sector where access, convenience, and trust now matter more than ever. Loblaw’s quiet expansion of in-store clinics and pharmacy services — four opened this quarter alone — reflects a deeper shift from transactional retail towards embedded community health provision.

Meanwhile, beauty products and over-the-counter remedies enjoyed a seasonal tailwind thanks to an extended flu season, but not all categories contributed equally. The company has made the deliberate move to exit low-margin electronics lines — a decision that might trim revenue in the short term but frees up space for better-performing categories. This kind of portfolio pruning is emblematic of a more mature retail strategy, one that’s less concerned with size for its own sake and more focused on margin-rich resilience.

There’s also a physical expansion story unfolding in parallel. Ten new food and drug stores opened during the quarter, alongside the second T&T Supermarket in downtown Toronto — a savvy move that caters to a growing demand for culturally specific offerings in urban centres. The company’s Hard Discount banners are quietly expanding into new communities, reaching shoppers who are far more sensitive to pricing pressures.

The new T&T Supermarket in downtown Toronto signals Loblaw’s ongoing investment in culturally diverse retail offerings.

Financially, the company has kept its balance sheet tidy. Operating income rose 5.2% to $906 million, and adjusted EBITDA ticked up to $1.59 billion. Gross profit grew 3.7%, and while gross margin was slightly lower, down 10 basis points, it remained firm at 31.5%. These aren’t show-stopping figures, but they suggest operational control in an inflationary environment.

Loblaw’s financial services arm delivered a more subdued performance. Revenue was up 3.3%, largely due to gains at The Mobile Shop™ and interchange income, but earnings before income tax dipped 31.8%. This was largely due to reduced marketing support compared to the prior year, and rising loyalty costs — the trade-off of building a stickier ecosystem around its PC Insiders World Elite Mastercard®. It’s a hit to the short-term bottom line, but arguably an investment in long-term customer lifetime value.

One theme that quietly underpins the entire quarter is capital allocation. Loblaw repurchased 2.49 million shares at a cost of $457 million and raised its quarterly dividend by 10% — the fourteenth consecutive annual increase. This is a company that not only generates cash but also knows how to return it strategically.

Then there’s ESG — an increasingly central metric for long-term performance. In its latest Live Life Well® report, Loblaw detailed a 16% reduction in enterprise emissions since 2020 and the diversion of over 80,000 tonnes of food waste from landfill. These aren’t headline-grabbing stats, but they’re tangible. More impressively, the company contributed more than $212 million to community initiatives, with its President’s Choice Children’s Charity reaching nearly one million students this school year.

None of this is accidental. It reflects a retailer that sees prosperity not just in profit margins but in social equity and environmental stewardship. And that matters — not just because consumers are demanding it, but because it increasingly defines what a “future-proof” business looks like.

Looking ahead, Loblaw has every intention of sticking to its knitting. The company expects high single-digit EPS growth for the full year and plans to invest a net $1.9 billion in its store network and distribution centres. It’s also expecting a mild accounting tailwind from a 53rd week in the fiscal calendar — a bonus rather than a strategy, but one that will pad results nonetheless.

What’s refreshing about Loblaw’s Q1 performance is that it doesn’t pretend to be revolutionary. There’s no dramatic pivot, no reinvention-of-the-wheel rhetoric. Just solid fundamentals, well-executed priorities, and a long-term vision that doesn’t lose its focus chasing quarterly spikes. In today’s retail world, that’s not playing it safe — it’s playing it smart.

A New Chapter for Naturopathic Medicine in Orangeville

0

Dr. Kelly McGuire officially opened The Health Practice at 229 Broadway, Unit #2, in Orangeville. The ribbon-cutting ceremony drew friends, family, patients and local officials, marking the first dedicated naturopathic clinic in the town’s downtown core.Dr. McGuire, an Orangeville native with 13 years of naturopathic experience, described the opening as the culmination of a long-held goal. “I’m honoured to join Orangeville’s community of locally owned businesses,” she said. “Our aim is to enrich integrative healthcare options that residents both need and deserve.”

Regional Barriers to Holistic Care

Despite increasing public interest in complementary and integrative medicine, residents of Orangeville and the surrounding Dufferin County still face several obstacles:

  • Practitioner Shortage: Until now, no full-time naturopathic clinics operated in Orangeville. Patients often endured lengthy waits or traveled to larger centres such as Toronto or Burlington.
  • Insurance Limitations: While many extended health plans recognize naturopathic services, coverage is often partial—leaving significant out-of-pocket costs and deterring some from seeking care.
  • Awareness and Referral Gaps: Misunderstandings about the scope of naturopathic practice—beyond lifestyle advice and supplements—mean fewer early referrals from family physicians and specialists.

Dr. McGuire intends to address these issues by offering extended evening and weekend hours, direct billing to major insurers, and an education series for both patients and healthcare providers on integrative care models.

Scope and Collaboration

Naturopathic medicine in Ontario operates under a regulated scope that includes primary-care modalities—blood work, lifestyle and nutrition plans, supplement protocols and, in Dr. McGuire’s case, intravenous vitamin therapy. “When pharmaceuticals or advanced imaging are required, we refer back to family doctors,” she explained, underscoring a collaborative approach rather than a standalone service.

Community Response and Future Plans

Orangeville Councillor Joe Andrews, chair of the Economic Development Committee, noted that the new clinic “expands local health options and underscores the entrepreneurial spirit vital to our downtown.” Mayor Lisa Post added that a diversified mix of healthcare services “strengthens community ties and brings more people into the core.”Looking ahead, The Health Practice plans to bring on-site a Registered Massage Therapist, Registered Social Worker and a clinical nutritionist—to create a multi-disciplinary hub and reduce patient wait times. A junior associate naturopath may follow once patient demand grows.
Dr. McGuire, who has lived and raised her family in Orangeville for over a decade, said the clinic represents both a professional milestone and a deeper personal connection to the community. She hopes to work alongside local schools, businesses and medical practitioners to improve access to preventive and natural healthcare across Dufferin County.

Metro Leads the “Buy Canadian” Boom: Q2 Sales Soar on Local Loyalty

0

Trade Tensions Ignite Local Loyalty

Canada’s 25 % counter-tariffs on U.S. goods, effective 4 March 2025, have intensified consumer nationalism and price pressures across the aisle.

A Leger poll taken in mid-April found 76 % of Canadians have consciously increased their purchases of domestic brands, the highest reading since February.

Canadian Products Pull Ahead at Metro

Metro Inc.—whose banners include Metro, Food Basics, Super C and Jean Coutu—reports that sales of Canadian-made items are now rising faster than overall store sales, and the gap is widening weekly.

To capture the surge, the grocer has:

  • Added bold maple-leaf shelf tags and “Made in Canada” filter buttons online
  • Featured local brands in weekly flyers and loyalty-app push notifications
  • Piloted end-cap “Canadian Choice” displays in high-traffic stores

Pharmacy Wins: Jean Coutu’s Local Advantage

The patriotism effect extends beyond groceries. Metro’s pharmacy division posted 7.0 % same-store growth, outpacing prescription and front-store averages industry-wide. Executives credit Canadian vitamin, supplement and OTC categories for the lift, alongside expanded generic drug offerings.

Financial Snapshot—Q2 2025

Metric Q2 2025 YoY Change Notes
Sales $4.91 billion ↑ 5.5 % Christmas shopping days shifted into Q2
Food same-store sales ↑ 5.3 % Online food sales +26.2 %
Pharmacy same-store sales ↑ 7.0 % Rx +7.8 %; front store +5.3 %
Net earnings $220 million ↑ 17.6 % EPS $0.99
Adj. net earnings $226.6 million ↑ 9.8 % EPS $1.02

Supply-Chain Playbook for Health & Wellness Retailers

  • Diversify Inputs: Metro is leaning on European, Latin-American and domestic suppliers to soften tariff impact.
  • Collaborate on Cost Sharing: Six-week notice periods give vendors time to re-quote and mitigate sudden price spikes.
  • Label with Clarity: Prominent origin tags—maple-leaf for Canada, “T” for tariff-affected U.S. items—help shoppers vote with their wallets and build trust.

What It Means for Readers

Drugstores and health-food retailers can ride the same wave by:

  1. Featuring Canadian-formulated supplements and natural health products in front-of-store promotions.
  2. Using geo-targeted email and SMS to highlight local brands available for curb-side pickup.
  3. Negotiating joint marketing funds with domestic vendors to offset promotional costs.

“We’re well positioned to grow in any environment, but spotlighting Canadian products is resonating with customers like never before,” says CEO Eric La Flèche.

Takeaway

The “Buy Canadian” movement has shifted from slogan to sales driver. For retailers in every health-adjacent category, clear origin labelling, local assortment depth and agile sourcing are now critical parts of the inflation playbook—because patriotism, it turns out, rings the till.

Trump’s Tariffs Unlikely to Trigger Sharp Price Increases in Canada

0

Trump’s Tariffs Unlikely to Trigger Sharp Price Increases in Canada, Economists Say—Some Products May Even Become Cheaper

Experts indicate many concerns persist, yet rapid inflation in consumer products is likely not one of them.

As the United States engages in a significant trade dispute with China, sharply driving up prices south of the border, Canadians are increasingly concerned about how this may affect their financial well-being.

While economists caution that Canada’s economy could experience slower growth due to broader global uncertainty sparked by former U.S. President Donald Trump’s aggressive tariffs, they note that significant price increases in electronics, clothing, food, appliances, and other consumer items are unlikely to occur immediately.

Why Some Canadian Prices Could Drop

RBC economist Claire Fan emphasizes that the Canadian government’s retaliatory tariffs on American products were carefully selected to minimize direct impacts on Canadian consumers, thus helping keep inflation close to the Bank of Canada’s target rate of two per cent by the end of 2025.

“Canadian pricing structures will predominantly reflect how effectively global supply chains adapt, the stability of the Canadian dollar, and corporate decisions regarding whether to pass increased costs onto consumers,” Fan explained.

William Huggins, Professor of Finance and Business Economics at McMaster University, suggests that in the short term, prices for certain consumer goods could actually fall. The United States has imposed 145 per cent duties on Chinese goods, significantly reducing China’s access to the American market and potentially creating an oversupply scenario globally.

“We might witness lower prices due to aggressive discounting from Chinese manufacturers attempting to redirect products to other markets, including Canada,” said Huggins.

While Canada’s anti-dumping regulations will protect certain domestic industries, Canadian consumers stand to benefit from lower-priced clothing, furniture, and electronics from China—sectors not robustly produced domestically.

Long-Term Risks and Currency Strength

However, Huggins cautioned that the benefits might be short-lived. If decreased U.S. demand leads China to reduce its production capacities significantly, prices could eventually climb due to tighter global supply. Additionally, logistics costs could rise for Canada, as the country will no longer be able to rely on shared logistics efficiencies derived from high-volume U.S. shipments.

Recent gains in the Canadian dollar also provide a buffer against inflation by reducing the cost of imports. The loonie recently strengthened, reaching a five-month peak at 72 cents (U.S.), partly due to depreciation in the American dollar.

Shaun Osborne, Chief Currency Strategist at Scotiabank, predicts further strengthening: “We anticipate continued short-to-medium-term strengthening of the Canadian dollar, which should act as a stabilizing force against inflationary pressures.”

Given the current trade conditions, Osborne forecasts a general slowdown in global economic growth, reducing demand pressures and helping keep inflation “stable or potentially lower.”

“A steady Canadian dollar coupled with subdued global demand would help manage domestic price levels,” Osborne concluded.

Ultimately, the extent of price fluctuations will largely hinge on how businesses choose to manage tariff-related cost increases.

Simeon Siegel, Retail and E-commerce Analyst at BMO Capital Markets, highlights that price increases will be tactical and targeted rather than widespread.

“When faced with increased costs, companies have three main options: raising prices, cutting expenses in other areas, or absorbing the higher costs themselves,” Siegel explained. “Most retailers are highly cautious about losing customers and will avoid blanket price hikes. They will instead strategically adjust prices, carefully balancing profitability and customer retention.”

Form Meets Function: How Calcium Salts Influence the Gut Microbiome During Fiber Fermentation

0

By Olivier Felicio

For years, calcium has been viewed primarily through the lens of skeletal health. But new research is pushing beyond the bones—highlighting calcium’s nuanced role in shaping the gut microbiome, particularly during the fermentation of prebiotic fibres like inulin and lactose. For formulators, nutritionists, and integrative health practitioners, these findings present an important shift: the form of calcium used in a formulation can influence microbial balance, metabolic outputs, and ultimately, nutrient absorption.

A recent in vitro study investigated how three common calcium salts—calcium phosphate (CaPi), calcium citrate (CaCi), and calcium carbonate (CaCa)—affect microbial diversity and short-chain fatty acid (SCFA) production in simulated colonic conditions. These fermentations were carried out under varying pH levels, mimicking the natural gradients of the colon, to examine how local environments modulate these effects.

Key Takeaways for Clinical and Product Strategy

  • Calcium Phosphate (CaPi) showed consistent microbiome modulation across all pH gradients. It promoted beneficial genera like Leuconostoc early in fermentation and Blautia after 24 hours, while suppressing Bacteroides, a genus often elevated in Western dietary patterns associated with inflammation and metabolic imbalance.
  • Calcium Citrate (CaCi) enhanced acetate production, particularly in low and high-pH environments. Acetate is a major SCFA associated with maintaining gut barrier function, supporting mucosal immunity, and regulating host metabolism.
  • Calcium Carbonate (CaCa) drove lactate production under low and medium pH levels. Lactate serves as a precursor for other SCFAs and is integral to cross-feeding interactions between microbial species—highlighting its potential value in shaping a resilient microbial ecosystem.
  • Bifidobacterium, a core genus in probiotic formulations, remained above 1% abundance across all conditions, suggesting resilience to both calcium form and pH variability—useful information for practitioners concerned about the survivability of probiotics in diverse gut environments.

Why This Matters for Practitioners and Product Developers

This study reinforces the importance of ingredient synergy for those working at the intersection of clinical nutrition and functional formulation. The form of calcium selected can influence more than bioavailability—it can shape fermentation pathways, select beneficial microbes, and modulate the production of metabolites with systemic effects.

This is especially relevant when designing products for:

  • Gut health and microbiome support
  • Postbiotic-rich formulations
  • Calcium supplementation for individuals with GI sensitivities
  • Nutritional interventions for metabolic or inflammatory conditions

Strategic Considerations

  • When formulating synbiotic products (combining prebiotics and probiotics), choosing the appropriate calcium salt may enhance outcomes by selectively influencing microbial composition during fermentation.
  • Practitioners recommending inulin or lactose-based prebiotics should be aware that calcium form—and individual pH variability—may affect how those fibres are metabolized and which microbes dominate the fermentation process.
  • The study underscores the importance of colonic pH as a variable in gut health—a parameter rarely discussed in clinical settings but essential in understanding interindividual responses to supplementation.

Calcium isn’t just about bones anymore. In the context of fibre fermentation and microbiome health, form matters. As research continues to illuminate the microbiota-nutrient interface, practitioners and product developers have a growing opportunity to personalize interventions based not only on nutrient needs—but on how those nutrients interact with the complex ecology of the gut.

Key Findings at a Glance

Calcium Phosphate (CaPi)

  • Promotes Leuconostoc (early) and Blautia (later)
  • Suppresses Bacteroides across all pH levels
  • Supports microbial diversity

Calcium Citrate (CaCi)

  • Increases acetate production at low/high pH
  • May enhance mucosal health and systemic metabolism

Calcium Carbonate (CaCa)

  • Boosts lactate production at low/medium pH
  • Encourages SCFA cross-feeding among microbes

Bifidobacterium

  • Remains stable across all calcium forms and pH levels (>1%)
  • Reliable component in probiotic formulas

Practical Takeaways for Product Developers

When designing supplements that include prebiotics like inulin or lactose, the choice of calcium salt matters. For example:

  • Synbiotic formulas could benefit from CaPi’s ability to selectively boost beneficial microbes like Blautia.
  • Postbiotic-focused products might leverage CaCi for its acetate-enhancing effect.
  • GI-support formulations for sensitive populations may do better with CaCa, especially where lactate production is desirable.

These findings also validate the functional use of minerals beyond RDI targets. Calcium form isn’t just a delivery system—it’s an active influencer of microbial ecology and metabolic signalling.


Formulator’s Note: Colonic pH as a Hidden Variable

pH variability in the colon—shaped by diet, stress, medication, and disease—can change how fibres are fermented and how microbes respond to minerals. Consider formulating with pH adaptability in mind, or educating clients on lifestyle factors that may affect colonic pH (e.g., high-protein diets may lower it).


Clinical Insights for Practitioners

For integrative clinicians, this research suggests new avenues for personalized micronutrient strategies. In patients with gut dysbiosis, metabolic disorders, or poor SCFA production, calcium form may act as a therapeutic lever when paired with the right prebiotics.

Additionally, this study supports the use of targeted formulations for different sections of the colon, based on localized pH gradients and microbial patterns.


Calcium Form vs. Microbiome Impact Chart

 

Calcium Salt Boosts Reduces SCFA Impact Best Use Case
CaPi LeuconostocBlautia Bacteroides ↑ Lactate Synbiotic formulations, gut inflammation support
CaCi Acetate-producing microbes Bacteroides (pH dependent) ↑ Acetate Metabolic support, gut barrier repair
CaCa Lactate-producing microbes Bacteroides (pH dependent) ↑ Lactate GI-sensitive clients, early-stage postbiotic support

Loblaw Enters Automatic Share Purchase Plan to Support Ongoing NCIB Repurchases

0

Loblaw Companies Limited (TSX: L); (“Loblaw”) announced today that it has entered into an automatic share purchase plan (“ASPP”) with a broker to facilitate repurchases of Loblaw’s common shares (“Common Shares”) under its previously announced normal course issuer bid (“NCIB”).

Loblaw previously announced that it had received approval from the Toronto Stock Exchange (“TSX”) to, during the 12 months commencing May 6, 2024 and terminating May 5, 2025, purchase up to 15,336,875 Common Shares, representing approximately 5% of the 306,737,513 Common Shares issued and outstanding as of April 22, 2024, by way of a NCIB on the TSX or through alternative trading systems or by such other means as may be permitted under applicable law.

During the effective period of Loblaw’s ASPP, Loblaw’s broker may purchase Common Shares at times when Loblaw would not be active in the market due to insider trading rules and its own internal trading blackout periods. Purchases will be made by Loblaw’s broker based upon parameters set by Loblaw when it does not have any material non-public information about itself and its securities and in accordance with the terms of the ASPP. Outside of the effective period of the ASPP, Common Shares may continue to be purchased in accordance with Loblaw’s discretion, subject to applicable law. The ASPP has been entered into under the requirements of applicable Canadian securities laws.

VEGAIN Enters National Distribution

0

Independent Canadian sports nutrition brand VEGAIN has reached a major milestone in its growth journey. The company has secured national distribution through Raw Elements, launched a public equity crowdfunding campaign on FrontFundr, and introduced a patent-pending innovation: SURGE™ Clear Protein.

These developments mark VEGAIN’s transition from a fast-growing direct-to-consumer brand to a national player in the plant-based sports nutrition market.

Retail Expansion with Raw Elements
Through its new partnership with Raw Elements—one of Canada’s top natural health distributors—VEGAIN’s high-performance, 100% plant-based products will soon be available in retail locations across the country.

“Raw Elements is known for representing the best in natural health and sports nutrition. We’re thrilled to work with them to bring VEGAIN to more customers across Canada,” said Edan Wolk, Founder & CEO of VEGAIN.

“VEGAIN is a brand that resonates with today’s conscious consumer. It’s innovative, high-performance, and values-driven,” added Olivia Haddad, General Manager at Raw Elements.

Community Investment Now Open
VEGAIN has also launched an equity crowdfunding campaign on FrontFundr, allowing everyday Canadians to invest in the company.

“We’ve built this company alongside our community, and now they can truly be part of it,” said Wolk.

The capital raised will support national retail expansion, operational growth, and the upcoming commercial debut of SURGE™ Clear Protein.

Introducing SURGE™ Clear Protein
SURGE™ Clear Protein is a patent-pending innovation that redefines what vegan protein can be. Unlike traditional powders with thick textures and chalky mouthfeel, SURGE™ dissolves fully in water, delivering a clean, refreshing, juice-like drink. It is sugar-free, smooth, and free of bitterness—available as both a ready-to-mix powder and a ready-to-drink can.

This product addresses a growing demand for functional, clean-label, plant-based nutrition designed for modern lifestyles.

What’s Ahead
With national retail expansion, a growing base of community investors, and a new category-defining product, VEGAIN is entering its most exciting phase yet.

“We’re not here to ride the wave of plant-based nutrition—we’re here to lead it,” said Wolk.

About VEGAIN
VEGAIN is a Canadian independent sports nutrition brand offering 100% plant-based, high-performance products. Built on sustainability, innovation, and community, VEGAIN is redefining how active individuals fuel their performance.

About Raw Elements
Raw Elements is a Canadian distributor of premium natural health products, known for supporting innovative, ethically-driven brands in wellness, sports, and functional nutrition.

Red vs White Wine: Is One Riskier for Cancer? New Study Weighs In

0

For years, red wine has been held in high regard, and praised for its potential health benefits, particularly due to its rich antioxidant content. White wine, on the other hand, often lingers in the background of this debate, rarely receiving the same level of scrutiny. However, a recent study published in the journal Nutrients has challenged the assumption that red wine is the “healthier” choice—at least when it comes to cancer risk.

The study in question, a meta-analysis of observational research, examined whether there are any significant differences in cancer risk between red and white wine drinkers. The findings? Red and white wine appear to be equally carcinogenic, though white wine may pose a greater risk for skin cancer. Let’s dive deeper into the implications of this research and what it means for those who enjoy a glass of wine with dinner.

The Carcinogenic Effects of Alcohol

Alcohol has long been recognized as a carcinogen. The International Agency for Research on Cancer (IARC) classified alcoholic beverages as Group 1 carcinogens several decades ago, placing them in the same category as tobacco and asbestos. This means there is sufficient evidence to confirm that alcohol consumption directly contributes to cancer development.

In 2020, alcohol consumption was responsible for approximately 4.1% of global cancer cases, with bowel cancer and breast cancer being among the most commonly linked malignancies. The underlying mechanism is well understood: when alcohol is metabolized in the liver, it converts into acetaldehyde, a toxic compound that damages DNA and proteins, increasing the likelihood of mutations.

Despite these well-documented risks, many people continue to perceive red wine as a somewhat “healthier” alcoholic option, largely due to its polyphenol content. Compounds such as resveratrol, tannins, and flavonoids have been linked to potential health benefits, including anti-inflammatory and antioxidant effects. But do these benefits outweigh the risks? The latest research suggests otherwise.

New Study: Red vs White Wine and Cancer Risk

A recent meta-analysis published in Nutrients sought to answer a fundamental question: does drinking red wine pose a lower cancer risk compared to white wine? The researchers analyzed data from 42 observational studies, including both cohort and case-control studies, to determine if there were any significant differences in cancer risk based on the type of wine consumed.

Key Findings:

  • Overall Cancer Risk: The study found no significant difference between red and white wine consumption in terms of overall cancer risk. The relative risks (RRs) were 0.98 for red wine and 1.00 for white wine—essentially the same.
  • White Wine and Skin Cancer: White wine consumption was associated with a 22% increased risk of skin cancer compared to red wine. This was one of the most striking findings of the study.
  • Gender Differences: While no significant difference in cancer risk was observed between red and white wine in men, the association was significant in women. This suggests potential hormonal or metabolic factors at play.
  • Breast Cancer Risk: Both red and white wine were associated with an increased risk of breast cancer, with no notable difference in incidence rates between the two.
  • Dose-Response Analysis: When examining case-control data, researchers found that consuming an additional 10 grams of ethanol from red wine per day increased overall cancer risk by 5%. However, this association was not observed in cohort studies.

These findings challenge the widespread belief that red wine is the “healthier” choice simply because it contains more antioxidants. The study suggests that, at least in terms of cancer risk, red wine offers no protective benefit over white wine.

Why Might White Wine Be Linked to a Higher Skin Cancer Risk?

One of the most unexpected findings in this study was the increased risk of skin cancer associated with white wine consumption. While the exact mechanisms remain unclear, there are several potential explanations:

  1. Acetaldehyde Levels: White wine has been found to contain higher levels of acetaldehyde than red wine. Since acetaldehyde is a known carcinogen, this could contribute to an elevated cancer risk, particularly in tissues exposed to oxidative stress.
  2. Lack of Protective Polyphenols: Red wine contains significantly more polyphenols, such as resveratrol and tannins, which have been studied for their potential anticancer properties. White wine, being lower in these compounds, may not offer the same level of cellular protection.
  3. UV Sensitisation: Some studies have suggested that certain compounds in white wine could increase photosensitivity, making skin cells more vulnerable to damage from ultraviolet (UV) radiation. This could potentially contribute to an increased risk of skin cancer.

While further research is needed to confirm these hypotheses, the findings suggest that white wine drinkers may need to be particularly mindful of their sun exposure.

What Does This Mean for Wine Drinkers?

For those who enjoy the occasional glass of wine, this study serves as a sobering reminder that no form of alcohol is truly “safe” when it comes to cancer risk. While moderate wine consumption is often promoted for its potential cardiovascular benefits, the latest research reinforces that both red and white wine carry carcinogenic risks.

Should You Stop Drinking Wine?

That depends on individual health priorities. If reducing cancer risk is a primary concern, limiting alcohol intake—or avoiding it altogether—is the most effective strategy. The World Health Organization (WHO) has consistently stated that there is no safe level of alcohol consumption when it comes to cancer prevention.

If You Choose to Drink, Consider These Tips:

Limit Intake: Stick to the lowest possible amount. Current UK guidelines recommend no more than 14 units of alcohol per week (approximately 6 medium glasses of wine) spread over at least three days.

Stay Hydrated: Drinking plenty of water can help minimize some of the dehydrating effects of alcohol.

Prioritise Antioxidant-Rich Foods: If antioxidants are a concern, it’s far better to get them from whole foods like berries, nuts, and dark leafy greens rather than relying on wine.

Be Sun-Safe: If you’re a white wine drinker, be extra cautious with sun exposure. Wear sunscreen and protective clothing to minimize skin cancer risk.

 The Wine Myth Busted

The romanticized notion that red wine is a “health food” has been challenged time and time again, and this latest study is yet another nail in the coffin of that idea. While red wine does contain antioxidants, the carcinogenic effects of alcohol appear to outweigh any potential benefits. More importantly, this research highlights that white wine may pose an even greater risk for certain cancers, particularly skin cancer.

Ultimately, the decision to drink wine—or any alcoholic beverage—should be an informed one. If you choose to indulge, do so in moderation, but be aware that when it comes to cancer risk, neither red nor white wine gets a free pass.

Further Reading & References:

  • Lim, R. K., Rhee, J., Hoang, M., et al. (2025) Consumption of Red Versus White Wine and Cancer Risk: A Meta-Analysis of Observational Studies. Nutrients, 17(3); 534. doi:10.3390/nu17030534.
  • International Agency for Research on Cancer (IARC). Alcohol Consumption and Cancer Risk.
  • World Health Organization (WHO). Global Status Report on Alcohol and Health 2023.

Gluconolactone: A Breakthrough for Targeted Lupus Therapy

0

New research highlights the potential of this naturally occurring compound in restoring immune balance and reducing inflammation in lupus patients.

By Olivier Felicio

A New Approach to Lupus Treatment

Lupus is a chronic autoimmune disease in which the body’s immune system mistakenly attacks its own tissues, leading to widespread inflammation and organ damage. The condition can affect multiple systems, including the skin, joints, kidneys, and nervous system. Traditional treatment options rely on immunosuppressive drugs, which help control disease progression but often come with significant side effects, including increased susceptibility to infections.

A recent study co-led by the University of Zurich (UZH), in collaboration with Harvard Medical School and Beth Israel Deaconess Medical Center, has identified a promising alternative. Researchers found that gluconolactone, a naturally occurring compound, may help restore immune balance in lupus patients without suppressing immune function. This discovery could pave the way for more targeted therapies with fewer adverse effects.

How Gluconolactone Restores Immune Balance 

A key aspect of lupus pathology is the dysfunction of regulatory T cells (Tregs), which normally prevent the immune system from attacking the body’s own tissues. When these cells fail to function properly, unchecked inflammation leads to disease progression.

The study, published in Science Translational Medicine, found that gluconolactone significantly increases both the number and function of Tregs. The research demonstrated:

  • Enhanced Treg production – The compound promoted the formation of these immune-regulating cells in laboratory cultures.
  • Reduction of inflammatory responses – Gluconolactone inhibited two key pro-inflammatory T-helper cell subgroups involved in autoimmune reactions.
  • Improved immune regulation in lupus models – Mice genetically engineered to develop lupus exhibited better Treg function and reduced inflammatory skin rashes after gluconolactone treatment.

Dr Antonios Kolios, a lead researcher in the study and a group leader at the Department of Dermatology at UZH, describes gluconolactone as a “power food” for regulatory T cells. “This is a real win-win situation for immune balance and inflammation control,” he explains.

Beyond laboratory and animal studies, gluconolactone has shown promise in human patients with cutaneous lupus, a form of the disease that primarily affects the skin.

In a clinical study, a topical cream containing gluconolactone led to visible improvements within two weeks. Patients experienced a reduction in skin inflammation without the side effects commonly associated with corticosteroids or immunosuppressive therapies.

This suggests that gluconolactone could be developed into targeted treatments for lupus and other autoimmune conditions, offering a natural and potentially safer alternative to existing medications.

Potential Applications Beyond Lupus

Given its ability to strengthen regulatory T cells and curb excessive immune responses, researchers believe gluconolactone may also be beneficial in treating other autoimmune diseases, including:

  • Psoriasis – a chronic inflammatory skin disorder
  • Rheumatoid arthritis – an autoimmune condition that affects the joints
  • Multiple sclerosis – a disease impacting the nervous system

While the early findings are promising, further clinical trials are necessary to establish gluconolactone’s efficacy across these conditions.

Dr Kolios has already filed a patent for the use of gluconolactone in autoimmune therapies, indicating confidence in its potential as a viable treatment option.

Before gluconolactone-based therapies can be made widely available, additional research is required to validate its long-term safety and effectiveness. The next phase of research will focus on:

  • Larger clinical trials to confirm the compound’s effects in human patients.
  • Comprehensive safety evaluations to rule out potential long-term side effects.
  • Development of different formulations, including oral, injectable, and topical applications, to determine the most effective method of delivery.

While these steps are necessary before regulatory approval, the findings thus far indicate that gluconolactone may represent a new generation of natural, immune-modulating therapies for lupus and other autoimmune diseases.

Researchers have identified gluconolactone as a potential treatment for lupus, offering new hope for targeted immune regulation.

Conclusion

The discovery of gluconolactone’s immune-modulating properties offers new possibilities for lupus treatment. Unlike conventional immunosuppressants, this naturally occurring compound may help regulate immune function without compromising overall immune defences.

While further trials are necessary, the early evidence suggests that gluconolactone could lead to more effective, targeted treatments for lupus and other autoimmune conditions. For patients who struggle with the side effects of current therapies, this research represents a step towards a future with better disease management and improved quality of life.

The scientific community will continue to monitor developments in this area, but the potential of gluconolactone is already generating significant interest in the field of autoimmune research.


Sources:

  • University of Zurich. Gluconolactone restores immune regulation and alleviates skin inflammation in lupus-prone mice and in patients with cutaneous lupus. Science Translational Medicine. (2025).
  • Li, W., et al. doi.org/10.1126/scitranslmed.adp4447.

SurvivorRx Launches Groundbreaking Personalized Wellness Program for Cancer Survivors

0

SurvivorRx Launches Groundbreaking Personalized Wellness Program for Cancer Survivors

SurvivorRx, a pioneering wellness brand designed exclusively for cancer survivors, has officially launched, offering a first-of-its-kind approach to post-treatment health. With a focus on holistic, science-backed support, SurvivorRx provides personalized supplements, expert-driven education, and a thriving community to help survivors regain strength and vitality.

A New Era of Survivor Wellness

Co-founded by Dr. Joe Mignone, a seasoned oncologist with over 25 years of clinical experience, and his wife Marzena Mignone, a dedicated cancer caregiver, SurvivorRx was born from their shared mission to bridge the gap in survivorship care. Their experience revealed a lack of safe, targeted wellness solutions for those navigating life after cancer—many supplements on the market fail to consider survivors’ unique nutritional needs or include ingredients that may be contraindicated for certain cancers.

Determined to change that, the Mignones assembled a team of oncologists, pharmacists, and naturopaths to develop SurvivorRx’s inaugural collection: meticulously formulated supplements that address the critical health concerns of survivors, from immune support to inflammation balance and whole-body wellness.

Tailored Nutrition Backed by Science

SurvivorRx blends cutting-edge Western clinical science with Eastern healing traditions to support survivors’ specific health needs. The debut lineup includes:

  • SurvivorRx ImmunityPlus ($79) – A daily multi-supplement pack for immune and overall health support.
  • Breast Cancer ER+ and ER- Formulas ($119-$129) – Targeted formulations addressing the unique nutritional needs of breast cancer survivors.
  • Prostate Cancer Formula ($119-$139) – Designed for prostate cancer survivors to support optimal recovery and long-term well-being.

Each formula undergoes rigorous testing in FDA-verified, cGMP-certified U.S. facilities and features clinically researched ingredients, such as 3rd Generation Curcumin (backed by over 30 UCLA-led trials), sustained-release melatonin, and patented probiotics. SurvivorRx prioritizes purity, safety, and efficacy, ensuring only the highest-quality supplements reach the hands of those who need them.

A Personal Mission to Empower Survivors

“As an oncologist, I’ve seen firsthand how challenging post-cancer wellness can be,” says Dr. Joe Mignone, Co-Founder of SurvivorRx. “Not all supplements are created equal, and what works for one survivor may not be safe for another. SurvivorRx was created to give cancer survivors personalized solutions they can trust.”

For Marzena Mignone, the journey is personal:
“As a caregiver, I experienced the frustration of navigating survivorship without clear guidance. With Joe’s medical expertise, I was lucky to have direction—but I knew not everyone had that support. SurvivorRx exists to make survivorship easier, healthier, and safer for survivors and their loved ones.”

A Commitment to Survivorship Care

SurvivorRx is more than just supplements—it’s a movement dedicated to reshaping post-cancer wellness. Through education, expert guidance, and a supportive community, the brand aims to empower survivors with the tools they need to thrive beyond treatment.